多中心评估CT肝脏表面结节度评分用于丙型肝炎患者肝纤维化分期及预测肝脏相关事件
这项多中心回顾性研究纳入191例丙型肝炎慢性肝病患者,评估CT肝脏表面结节度(LSN)评分单独及联合FIB-4对进展期纤维化和肝硬化的诊断效能,并预测肝脏相关事件;LSN评分随纤维化分期升高而增加,联合FIB-4后AUC提高,且LSN评分是基线肝失代偿和未来肝脏相关事件的最强预测因子。
要点
- LSN评分随纤维化分期升高而增加,F4期均值3.19±0.89明显高于F0-F1期2.26±0.44(p<.001)。
- LSN评分单独诊断进展期纤维化(≥F3)AUC为0.87,诊断肝硬化(F4)AUC为0.89。
- LSN联合FIB-4后诊断进展期纤维化AUC升至0.92、肝硬化升至0.94(均p=.005)。
核心结论
- 在丙型肝炎慢性肝病多中心队列中,LSN评分单独及联合FIB-4对进展期纤维化和肝硬化均表现出较强诊断效能,LSN评分还可预测未来肝脏相关事件。
研究设计与样本
- 回顾性研究,5家学术医学中心各连续纳入40例丙型肝炎慢性肝病患者,最终纳入191例(女67例、男124例,平均年龄54岁),均在腹部CT前后6个月内接受非靶向肝活检;由单一中心读者使用软件测量LSN评分。
关键影像表现/征象
- LSN评分均值随纤维化分期升高而增加:F0-F1期2.26±0.44、F2期2.35±0.37、F3期2.42±0.38、F4期3.19±0.89(p<.001)。
诊断标准与关键数值
- LSN评分单独诊断进展期纤维化(≥F3)AUC为0.87,诊断肝硬化(F4)AUC为0.89。
- LSN联合FIB-4诊断进展期纤维化AUC为0.92、诊断肝硬化AUC为0.94(均p=.005)。
- 联合评分在最佳 cutoff 点诊断进展期纤维化敏感度75%、特异度82%,诊断肝硬化敏感度84%、特异度85%。
- 多变量模型中LSN评分是基线肝失代偿的最强预测因子(每增加1单位OR为14.28,p<.001),也是未来肝脏相关事件的预测因子(每增加1单位HR为2.87,p=.03)。
临床应用与阅片要点
- 作者认为LSN评分有理由在临床实践中作为定量标志物,用于检测进展期肝纤维化、代偿期肝硬化和失代偿期肝硬化,并预测丙型肝炎慢性肝病患者的未来肝脏相关事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. In single-institution multireader studies, the liver surface nodularity (LSN) score accurately detects advanced liver fibrosis and cirrhosis and predicts liver decompensation in patients with chronic liver disease (CLD) from hepatitis C virus (HCV). OBJECTIVE. The purpose of this study was to assess the diagnostic performance of the LSN score alone and in combination with the (FIB-4; fibrosis index based on four factors) to detect advanced fibrosis and cirrhosis and to predict future liver-related events in a multiinstitutional cohort of patients with CLD from HCV. METHODS. This retrospective study included 40 consecutive patients, from each of five academic medical centers, with CLD from HCV who underwent nontargeted liver biopsy within 6 months before or after abdominal CT. Clinical data were recorded in a secure web-based database. A single central reader measured LSN scores using software. Diagnostic performance for detecting liver fibrosis stage was determined. Multivariable models were constructed to predict baseline liver decompensation and future liver-related events. RESULTS. After exclusions, the study included 191 patients (67 women, 124 men; mean age, 54 years) with fibrosis stages of F0-F1 (n = 37), F2 (n = 44), F3 (n = 46), and F4 (n = 64). Mean LSN score increased with higher stages (F0-F1, 2.26 ± 0.44; F2, 2.35 ± 0.37; F3, 2.42 ± 0.38; F4, 3.19 ± 0.89; p < .001). The AUC of LSN score alone was 0.87 for detecting advanced fibrosis (≥ F3) and 0.89 for detecting cirrhosis (F4), increasing to 0.92 and 0.94, respectively, when combined with FIB-4 scores (both p = .005). Combined scores at optimal cutoff points yielded sensitivity of 75% and specificity of 82% for advanced fibrosis, and sensitivity of 84% and specificity of 85% for cirrhosis. In multivariable models, LSN score was the strongest predictor of baseline liver decompensation (odds ratio, 14.28 per 1-unit increase; p < .001) and future liver-related events (hazard ratio, 2.87 per 1-unit increase; p = .03). CONCLUSION. In a multiinstitutional cohort of patients with CLD from HCV, LSN score alone and in combination with FIB-4 score exhibited strong diagnostic performance in detecting advanced fibrosis and cirrhosis. LSN score also predicted future liver-related events. CLINICAL IMPACT. The LSN score warrants a role in clinical practice as a quantitative marker for detecting advanced liver fibrosis, compensated cirrhosis, and decompensated cirrhosis and for predicting future liver-related events in patients with CLD from HCV.
引用
- Elkassem, Allen, Lirette, et al. Multiinstitutional Evaluation of the Liver Surface Nodularity Score on CT for Staging Liver Fibrosis and Predicting Liver-Related Events in Patients With Hepatitis C. AJR Am J Roentgenol. 2021. PMID: 34935403. doi:10.2214/AJR.21.27062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。